Diabetes-related cardiac dysfunction

Endocrinology and Metabolism

Volumn 32, Issue 2, 2017, Pages 171-179

  Williams, Lamario J ^a   Nye, Brenna G ^a   Wende, Adam R ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Diabetic cardiomyopathies; Energy metabolism; Heart; Heart failure; Metabolic diseases; Mitochondria; Physiological; Stress

Indexed keywords

HORMONE;

CARDIOMETABOLIC RISK; CELL TRANSPORT; CELLULAR UPTAKE; DIABETIC CARDIOMYOPATHY; DISEASE COURSE; ENERGY YIELD; HUMAN; MOLECULAR PATHOLOGY; NONHUMAN; PROGNOSIS; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW (TOPIC);

EID: 85023169986     PISSN: 2093596X     EISSN: 20935978     Source Type: Journal    
DOI: 10.3803/EnM.2017.32.2.171     Document Type: Review

References (59)

1. Bozkurt B, Colvin M, Cook J, Cooper LT, Deswal A, Fonarow GC, et al. Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American Heart Association. Circulation 2016;134: e579-646
2. Lorenzo-Almoros A, Tunon J, Orejas M, Cortes M, Egido J, Lorenzo O. Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol 2017;16:28
3. Litwin SE. Diabetes and the heart: is there objective evidence of a human diabetic cardiomyopathy? Diabetes 2013; 62:3329-30
4. Holscher ME, Bode C, Bugger H. Diabetic cardiomyopathy: does the type of diabetes matter? Int J Mol Sci 2016;17: E2136
5. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC study 30-year ollow-up. Diabetes Care 2016;39:686-93
6. Hayward RA, Reaven PD, Wiitala WL, Bahn GD, Reda DJ, Ge L, et al. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;372: 2197-206
7. Kandula V, Kosuru R, Li H, Yan D, Zhu Q, Lian Q, et al. Forkhead box transcription factor 1: role in the pathogenesis of diabetic cardiomyopathy. Cardiovasc Diabetol 2016;15: 44
8. Guo CA, Guo S. Insulin receptor substrate signaling controls cardiac energy metabolism and heart failure. J Endocrinol 2017;233:R131-43
9. Fu Q, Wang Q, Xiang YK. Insulin and beta adrenergic receptor signaling: crosstalk in heart. Trends Endocrinol Metab 2017;28:416-27
10. Shah AD, Langenberg C, Rapsomaniki E, Denaxas S, Pujades-Rodriguez M, Gale CP, et al. Type 2 diabetes and incidence of cardiovascular diseases: a cohort study in 1.9 million people. Lancet Diabetes Endocrinol 2015;3:105-13
11. Steinberg D, Bennett GG, Svetkey L. The DASH diet, 20 years later. JAMA 2017;317:1529-30
12. Puckrein GA, Egan BM, Howard G. Social and medical determinants of cardiometabolic health: the big picture. Ethn Dis 2015;25:521-4
13. Esler M. Mental stress and human cardiovascular disease. Neurosci Biobehav Rev 2017;74(Pt B):269-76
14. Healy GN, Dunstan DW, Salmon J, Cerin E, Shaw JE, Zimmet PZ, et al. Breaks in sedentary time: beneficial associations with metabolic risk. Diabetes Care 2008;31:661-6
15. Dempsey PC, Owen N, Yates TE, Kingwell BA, Dunstan DW. Sitting less and moving more: improved glycaemic control for type 2 diabetes prevention and management. Curr Diab Rep 2016;16:114
16. Zhu Y, Zhang D, Zhou D, Li Z, Li Z, Fang L, et al. Susceptibility loci for metabolic syndrome and metabolic components identified in Han Chinese: a multi-stage genome-wide association study. J Cell Mol Med 2017;21:1106-16
17. Choi JW, Moon S, Jang EJ, Lee CH, Park JS. Association of prediabetes-associated single nucleotide polymorphisms with microalbuminuria. PLoS One 2017;12:e0171367
18. Ng MC. Genetics of type 2 diabetes in African Americans. Curr Diab Rep 2015;15:74
19. Wende AR. Post-translational modifications of the cardiac proteome in diabetes and heart failure. Proteomics Clin Appl 2016;10:25-38
20. Guo R, Nair S. Role of microRNA in diabetic cardiomyopathy: from mechanism to intervention. Biochim Biophys Acta 2017;1863:2070-7
21. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia 2014;57:660-71
22. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest 2005;115:1111-9
23. Xu Z, Kong XQ. Bixin ameliorates high fat diet-induced cardiac injury in mice through inflammation and oxidative stress suppression. Biomed Pharmacother 2017;89:991-1004
24. Ni R, Cao T, Xiong S, Ma J, Fan GC, Lacefield JC, et al. Therapeutic inhibition of mitochondrial reactive oxygen species with mito-TEMPO reduces diabetic cardiomyopathy. Free Radic Biol Med 2016;90:12-23
25. Saklani R, Gupta SK, Mohanty IR, Kumar B, Srivastava S, Mathur R. Cardioprotective effects of rutin via alteration in TNF-alpha, CRP, and BNP levels coupled with antioxidant effect in STZ-induced diabetic rats. Mol Cell Biochem 2016;420:65-72
26. Okonko DO, Shah AM. Heart failure: mitochondrial dysfunction and oxidative stress in CHF. Nat Rev Cardiol 2015; 12:6-8
27. Lal N, Chiu AP, Wang F, Zhang D, Jia J, Wan A, et al. Loss of VEGFB and its signaling in the diabetic heart is associated with increased cell death signaling. Am J Physiol Heart Circ Physiol 2017;312:H1163-75
28. Lopaschuk GD, Collins-Nakai RL, Itoi T. Developmental changes in energy substrate use by the heart. Cardiovasc Res 1992;26:1172-80
29. Luiken JJ, Glatz JF, Neumann D. Cardiac contraction-induced GLUT4 translocation requires dual signaling input. Trends Endocrinol Metab 2015;26:404-10
30. Belke DD, Larsen TS, Gibbs EM, Severson DL. Altered metabolism causes cardiac dysfunction in perfused hearts from diabetic (db/db) mice. Am J Physiol Endocrinol Metab 2000;279:E1104-13
31. Yan J, Young ME, Cui L, Lopaschuk GD, Liao R, Tian R. Increased glucose uptake and oxidation in mouse hearts prevent high fatty acid oxidation but cause cardiac dysfunction in diet-induced obesity. Circulation 2009;119:2818-28
32. van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res 2000;45:279-93
33. Fillmore N, Mori J, Lopaschuk GD. Mitochondrial fatty acid oxidation alterations in heart failure, ischaemic heart disease and diabetic cardiomyopathy. Br J Pharmacol 2014; 171:2080-90
34. Bayeva M, Sawicki KT, Ardehali H. Taking diabetes to heart: deregulation of myocardial lipid metabolism in diabetic cardiomyopathy. J Am Heart Assoc 2013;2:e000433
35. Crowley MJ, Diamantidis CJ, McDuffie JR, Cameron CB, Stanifer JW, Mock CK, et al. Clinical outcomes of metformin use in populations with chronic kidney disease, congestive heart failure, or chronic liver disease: a systematic review. Ann Intern Med 2017;166:191-200
36. Johnson R, Dludla P, Joubert E, February F, Mazibuko S, Ghoor S, et al. Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis. Mol Nutr Food Res 2016;60:922-34
37. Cotter DG, Schugar RC, Crawford PA. Ketone body metabolism and cardiovascular disease. Am J Physiol Heart Circ Physiol 2013;304:H1060-76
38. Des Rosiers C, Labarthe F, Lloyd SG, Chatham JC. Cardiac anaplerosis in health and disease: food for thought. Cardiovasc Res 2011;90:210-9
39. Wu P, Blair PV, Sato J, Jaskiewicz J, Popov KM, Harris RA. Starvation increases the amount of pyruvate dehydrogenase kinase in several mammalian tissues. Arch Biochem Biophys 2000;381:1-7
40. Lee IK. The role of pyruvate dehydrogenase kinase in diabetes and obesity. Diabetes Metab J 2014;38:181-6
41. Nielsen R, Jorsal A, Iversen P, Tolbod L, Bouchelouche K, Sorensen J, et al. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. J Nucl Cardiol 2016 Jul 29 [Epub]. https://doi.org/10.1007/s12350-016-0622-0
42. Chanda D, Luiken JJ, Glatz JF. Signaling pathways involved in cardiac energy metabolism. FEBS Lett 2016;590:2364-74
43. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117-28
44. Bernardi S, Michelli A, Zuolo G, Candido R, Fabris B. Update on RAAS modulation for the treatment of diabetic cardiovascular disease. J Diabetes Res 2016;2016:8917578
45. Fiordaliso F, Li B, Latini R, Sonnenblick EH, Anversa P, Leri A, et al. Myocyte death in streptozotocin-induced diabetes in rats in angiotensin II-dependent. Lab Invest 2000; 80:513-27
46. Sadoshima J, Izumo S. Molecular characterization of angiotensin II: induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993;73:413-23
47. Mishra N, Singh N. Blood viscosity, lipid profile, and lipid peroxidation in type-1 diabetic patients with good and poor glycemic control. N Am J Med Sci 2013;5:562-6
48. Zalesak M, BlaZicek P, Pancza D, Gablovsky I, Strbak V, Ravingerova T. Hyperosmotic environment blunts effectivity of ischemic preconditioning against ischemia-reperfusion injury and improves ischemic tolerance in non-preconditioned isolated rat hearts. Physiol Res 2016;65:1045-51
49. Fiordaliso F, Cuccovillo I, Bianchi R, Bai A, Doni M, Salio M, et al. Cardiovascular oxidative stress is reduced by an ACE inhibitor in a rat model of streptozotocin-induced diabetes. Life Sci 2006;79:121-9
50. Moore KJ, Sheedy FJ, Fisher EA. Macrophages in atherosclerosis: a dynamic balance. Nat Rev Immunol 2013;13: 709-21
51. Singh M, Arora R. Newer therapies for management of stable ischemic heart disease with focus on refractory angina. Am J Ther 2016;23:e1842-56
52. Wende AR, Abel ED. Lipotoxicity in the heart. Biochim Biophys Acta 2010;1801:311-9
53. Taegtmeyer H, Beauloye C, Harmancey R, Hue L. Insulin resistance protects the heart from fuel overload in dysregulated metabolic states. Am J Physiol Heart Circ Physiol 2013;305:H1693-7
54. Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, et al. The failing heart relies on ketone bodies as a fuel. Circulation 2016;133:698-705
55. Bedi KC Jr, Snyder NW, Brandimarto J, Aziz M, Mesaros C, Worth AJ, et al. Evidence for intramyocardial disruption of lipid metabolism and increased myocardial ketone utilization in advanced human heart failure. Circulation 2016;133: 706-16
56. Chen X, Zhao T, Huang X, Wu L, Wu K, Fan M, et al. Intermittent hypoxia maintains glycemia in streptozotocin-induced diabetic rats. Cell Stress Chaperones 2016;21:515-22
57. Zou L, Zhu-Mauldin X, Marchase RB, Paterson AJ, Liu J, Yang Q, et al. Glucose deprivation-induced increase in protein O-GlcNAcylation in cardiomyocytes is calcium-dependent. J Biol Chem 2012;287:34419-31
58. Jensen RV, Zachara NE, Nielsen PH, Kimose HH, Kristiansen SB, Botker HE. Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc Res 2013;97:369-78
59. Marsh SA, Powell PC, Dell'italia LJ, Chatham JC. Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart. Life Sci 2013;92:648-56